Роберто Пили
Memorial Sloan Kettering Cancer Center · 682 works · 19,587 citations · h-index 73
Top works
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.
- Kidney Cancer
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
- Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth
- VEGF 165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo
- The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
- Vinflunine in platinum‐pretreated patients with locally advanced or metastatic urothelial carcinoma
- Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α
- Kidney Cancer, Version 3.2015
- Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1
- Consensus guidelines for the use and interpretation of angiogenesis assays
- Testicular Cancer
- Targeting Tumor Angiogenesis with Histone Deacetylase Inhibitors: the Hydroxamic Acid Derivative LBH589
- Altered Angiogenesis Underlying Age-Dependent Changes in Tumor Growth
- The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584
- Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study
- Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
- The alpha-glucosidase I inhibitor castanospermine alters endothelial cell glycosylation, prevents angiogenesis, and inhibits tumor growth.
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer